Sitravatinib in Metastatic Breast Cancer
A Phase II Study of Sitravatinib in Metastatic, Pre-treated, Triple Negative Breast Cancer
Sponsor: Mirati Therapeutics Inc.
Terminated
Terminated by sponsor due to lack of interest
Other terminated trials from Mirati Therapeutics Inc.
- Advanced Solid Tumor · Phase PHASE1 · Feb 2026
- Advanced Solid Tumor · Phase PHASE1 · Mar 2025
- Metastatic Neoplasm · Phase PHASE1/PHASE2 · Apr 2024
- Advanced Treatment-Naïve PD-L1 · Phase PHASE2 · Oct 2023
- Urothelial Carcinoma · Phase PHASE2 · Aug 2022
More terminations from Mirati Therapeutics Inc.
This PHASE2 trial investigates Breast Cancer Metastatic and Breast Cancer Stage IV and is currently terminated or withdrawn. Mirati Therapeutics Inc. leads this study, which shows 10 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE2
Status: Withdrawn → Terminated
-
Apr 2024 — Jun 2024 [monthly]
Withdrawn PHASE2
Status: Terminated → Withdrawn
-
Feb 2023 — Apr 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
▶ Show 5 earlier versions
-
Sep 2021 — Feb 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2019 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mirati Therapeutics Inc.
- Xiang Zhang
For direct contact, visit the study record on ClinicalTrials.gov .